Peter R. Gebauer Sells 6,224 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider Peter R. Gebauer sold 6,224 shares of LeMaitre Vascular stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.85, for a total value of $210,682.40. Following the sale, the insider now directly owns 8,477 shares of the company’s stock, valued at $286,946.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

LeMaitre Vascular, Inc. (LMAT) opened at 32.99 on Friday. The firm has a market capitalization of $627.54 million, a PE ratio of 47.13 and a beta of 0.65. The firm has a 50-day moving average price of $31.03 and a 200-day moving average price of $27.38. LeMaitre Vascular, Inc. has a 1-year low of $16.80 and a 1-year high of $36.09.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The firm had revenue of $25.80 million during the quarter, compared to the consensus estimate of $25.42 million. During the same period last year, the business posted $0.14 EPS. The business’s revenue was up 15.2% compared to the same quarter last year. Equities analysts expect that LeMaitre Vascular, Inc. will post $0.80 earnings per share for the current fiscal year.

LeMaitre Vascular announced that its Board of Directors has authorized a share buyback program on Thursday, July 27th that allows the company to buyback $7.50 million in shares. This buyback authorization allows the medical instruments supplier to purchase up to 1.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd will be issued a dividend of $0.055 per share. The ex-dividend date of this dividend is Monday, August 21st. This represents a $0.22 dividend on an annualized basis and a yield of 0.67%. LeMaitre Vascular’s payout ratio is currently 31.88%.

TRADEMARK VIOLATION WARNING: “Peter R. Gebauer Sells 6,224 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://stocknewstimes.com/2017/08/12/peter-r-gebauer-sells-6224-shares-of-lemaitre-vascular-inc-nasdaqlmat-stock.html.

LMAT has been the subject of a number of analyst reports. Zacks Investment Research raised LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 price objective for the company in a research note on Friday, April 28th. Stifel Nicolaus lifted their price objective on LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 price objective on shares of LeMaitre Vascular in a research note on Thursday, April 27th. Benchmark Co. raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, July 28th. Finally, BidaskClub cut LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. LeMaitre Vascular currently has an average rating of “Buy” and a consensus target price of $30.17.

A number of hedge funds have recently modified their holdings of the company. Bahl & Gaynor Inc. increased its stake in shares of LeMaitre Vascular by 12.3% in the first quarter. Bahl & Gaynor Inc. now owns 48,585 shares of the medical instruments supplier’s stock valued at $1,197,000 after buying an additional 5,320 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of LeMaitre Vascular by 52.3% in the first quarter. Ameriprise Financial Inc. now owns 201,508 shares of the medical instruments supplier’s stock valued at $4,963,000 after buying an additional 69,186 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of LeMaitre Vascular by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock valued at $2,181,000 after buying an additional 1,408 shares in the last quarter. American Century Companies Inc. increased its stake in shares of LeMaitre Vascular by 27.7% in the first quarter. American Century Companies Inc. now owns 192,732 shares of the medical instruments supplier’s stock valued at $4,747,000 after buying an additional 41,848 shares in the last quarter. Finally, Algert Global LLC increased its stake in shares of LeMaitre Vascular by 93.9% in the first quarter. Algert Global LLC now owns 62,062 shares of the medical instruments supplier’s stock valued at $1,529,000 after buying an additional 30,062 shares in the last quarter. Hedge funds and other institutional investors own 67.10% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply